Goldman Sachs’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$432M Sell
1,476,183
-84,249
-5% -$27.7M 0.05% 393
2025
Q4
$547M Buy
1,560,432
+148,443
+11% +$50.2M 0.07% 274
2025
Q3
$456M Buy
1,411,989
+18,163
+1% +$5.65M 0.06% 330
2025
Q2
$542M Buy
1,393,826
+119,423
+9% +$48M 0.07% 257
2025
Q1
$554M Sell
1,274,403
-16,827
-1% -$6.75M 0.09% 223
2024
Q4
$476M Sell
1,291,230
-704,292
-35% -$295M 0.08% 240
2024
Q3
$1.04B Buy
1,995,522
+83,705
+4% +$44.7M 0.17% 104
2024
Q2
$1.04B Buy
1,911,817
+47,949
+3% +$25.3M 0.18% 100
2024
Q1
$966M Sell
1,863,868
-274,047
-13% -$136M 0.17% 105
2023
Q4
$1.01B Buy
2,137,915
+97,107
+5% +$44.9M 0.19% 92
2023
Q3
$889M Buy
2,040,808
+27,400
+1% +$12.4M 0.19% 95
2023
Q2
$895M Buy
2,013,408
+170,785
+9% +$78.8M 0.19% 85
2023
Q1
$847M Sell
1,842,623
-215,911
-10% -$103M 0.19% 89
2022
Q4
$1.06B Sell
2,058,534
-168,336
-8% -$85.5M 0.26% 59
2022
Q3
$1.01B Buy
2,226,870
+120,066
+6% +$57.4M 0.26% 58
2022
Q2
$1.02B Buy
2,106,804
+556,209
+36% +$275M 0.25% 59
2022
Q1
$762M Buy
1,550,595
+226,437
+17% +$104M 0.16% 100
2021
Q4
$614M Buy
1,324,158
+401,016
+43% +$169M 0.12% 149
2021
Q3
$344M Sell
923,142
-337,827
-27% -$128M 0.07% 249
2021
Q2
$481M Sell
1,260,969
-427,183
-25% -$163M 0.11% 164
2021
Q1
$606M Buy
1,688,152
+330,308
+24% +$106M 0.15% 111
2020
Q4
$436M Sell
1,357,844
-143,309
-10% -$44M 0.11% 162
2020
Q3
$403M Sell
1,501,153
-253,430
-14% -$68.2M 0.11% 154
2020
Q2
$461M Sell
1,754,583
-84,060
-5% -$22.4M 0.14% 132
2020
Q1
$417M Sell
1,838,643
-632,042
-26% -$172M 0.15% 126
2019
Q4
$746M Sell
2,470,685
-69,595
-3% -$19.2M 0.19% 92
2019
Q3
$610M Buy
2,540,280
+263,857
+12% +$72.3M 0.18% 97
2019
Q2
$642M Buy
2,276,423
+284,621
+14% +$77.7M 0.18% 91
2019
Q1
$572M Buy
1,991,802
+448,018
+29% +$130M 0.17% 97
2018
Q4
$405M Sell
1,543,784
-248,551
-14% -$68.3M 0.13% 130
2018
Q3
$491M Sell
1,792,335
-214,873
-11% -$55.8M 0.13% 145
2018
Q2
$478M Sell
2,007,208
-817,088
-29% -$189M 0.13% 141
2018
Q1
$620M Sell
2,824,296
-560,429
-17% -$132M 0.16% 113
2017
Q4
$762M Buy
3,384,725
+905,807
+37% +$193M 0.18% 85
2017
Q3
$471M Buy
2,478,918
+257,810
+12% +$49.1M 0.12% 152
2017
Q2
$418M Buy
2,221,108
+7,603
+0.3% +$1.37M 0.11% 166
2017
Q1
$366M Buy
2,213,505
+28,590
+1% +$4.55M 0.1% 184
2016
Q4
$314M Buy
2,184,915
+402,963
+23% +$54M 0.09% 213
2016
Q3
$223M Buy
1,781,952
+103,666
+6% +$13.4M 0.07% 301
2016
Q2
$220M Sell
1,678,286
-108,126
-6% -$14.8M 0.07% 310
2016
Q1
$248M Buy
1,786,412
+297,059
+20% +$39.7M 0.08% 259
2015
Q4
$208M Buy
1,489,353
+106,214
+8% +$14.6M 0.07% 336
2015
Q3
$194M Buy
1,383,139
+31,836
+2% +$4.78M 0.07% 318
2015
Q2
$222M Sell
1,351,303
-269,937
-17% -$43.1M 0.07% 314
2015
Q1
$250M Sell
1,621,240
-216,262
-12% -$30.8M 0.08% 267
2014
Q4
$231M Buy
1,837,502
+200,139
+12% +$24.7M 0.07% 304
2014
Q3
$196M Buy
1,637,363
+103,699
+7% +$11.9M 0.06% 342
2014
Q2
$165M Buy
1,533,664
+288,806
+23% +$29.8M 0.05% 436
2014
Q1
$124M Sell
1,244,858
-376,851
-23% -$34.1M 0.04% 524
2013
Q4
$150M Buy
1,621,709
+864,296
+114% +$76.8M 0.05% 443
2013
Q3
$63.3M Sell
757,413
-106,818
-12% -$9.15M 0.02% 825
2013
Q2
$70.7M Buy
+864,231
New +$64.7M 0.03% 704

Other funds holding ELV

Goldman Sachs's ELV Position: Q1 2026 in Review

Goldman Sachs reduced its Elevance Health (ELV) stake by 5.4% in Q1 2026, selling an estimated $27.7M and leaving 1,476,183 shares worth $432M. The position accounts for 0.05% of the portfolio, ranked #393.

Goldman Sachs first reported a position in ELV in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.06B in Q4 2022. 1,462 funds tracked by Wall St. Rank hold ELV as of Q1 2026.

  • Goldman Sachs held 1,476,183 shares of Elevance Health worth $432M as of Q1 2026.
  • Goldman Sachs sold 84,249 Elevance Health shares in Q1 2026, an estimated $27.7M.
  • Elevance Health made up 0.05% of Goldman Sachs's portfolio in Q1 2026, its #393 holding.
  • Goldman Sachs first reported a position in Elevance Health in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's Elevance Health position peaked at $1.06B in Q4 2022.
  • 1,462 funds tracked by Wall St. Rank held Elevance Health as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.